42 results about "Pharmaceutical solvent" patented technology

The invention relates to the field of pharmaceutical compositions, and especially relates to a pharmaceutical composition preventing postoperative delirium. The provided pharmaceutical composition contains a pharmaceutical solvent carrier and dexmedetomidine or pharmaceutically-acceptable salts dissolving in the solvent carrier. The pharmaceutical composition is applicable to improve postoperative patient sleep structure, thereby improving patient sleep quality. The pharmaceutical composition is capable of preventing postoperative patient delirium, also is capable of mitigating patient pain, is safe to use and low in cost, and is usable by being matched with one or more of other sedatives, narcotics, hypnotics and opioids.

The present invention is drawn to adhesive peel-forming formulations for dermal delivery of a drug. The formulation can include a drug, a solvent vehicle, and a peel-forming agent. The solvent vehicle can include a volatile solvent system having one or more volatile solvent, and a non-volatile solvent system having one or more non-volatile solvent, wherein the non-volatile solvent system has a solubility for the drug that is within a window of operable solubility for the drug such that the drug can be delivered at therapeutically effective rates over a sustained period of time. The formulation can have a viscosity suitable for application to a skin surface prior to evaporation of the volatile solvents system. When applied to the skin, the formulation can form a solidified peelable layer after at least a portion of the volatile solvent system is evaporated.

The invention relates to pharmaceutical formulations, and more particularly to formulations containing cannabinoids for administration via a pump action spray. In particular, the invention relates to pharmaceutical formulations, for use in administration of lipophilic medicaments via mucosal surfaces, comprising: at least one lipophilic medicament, a solvent and a co-solvent, wherein the total amount of solvent and co-solvent present in the formulation is greater than 55% wt / wt of the formulation and the formulation is absent of a self emulsifying agent and / or a fluorinated propellant.

It has been confirmed that β-paradone has potent antitumor activity and inhibits human cancer lines, but its solubility in most pharmaceutical solvents is poor. The present invention overcomes this important defect by adopting a novel pharmaceutical composition, which contains an effective amount of β-paradone or its derivatives, analogs and pharmaceutical solubilizing carrier molecules, and the solubilizing carrier molecules can be It is a water-solubilizing carrier molecule, such as hydroxypropyl-β-cyclodextrin, or an oil-based solubilizing carrier molecule to enhance the solubility of β-paradone in an aqueous solution. An effective amount of β-paradone or its derivatives and analogs can be mixed with pharmaceutical solubilizing carrier molecules in an aqueous solution. The novel pharmaceutical compositions can be administered with a second anticancer agent, or in combination with radiation therapy. The invention also discloses a formula, which mixes pharmaceutical solubilizing carrier molecules with β-paladone or its derivatives and analogues, and after the mixture is freeze-dried, it is reconstituted in an aqueous solution to have effective solubility. The invention also provides the β-paladone emulsion in the excipient of the medicinal fat emulsion. The invention also discloses a method for treating cancer by administering the novel pharmaceutical composition and formulation to a sick body. The invention also provides a pharmaceutical kit.

The invention relates to the field of pharmaceutical compositions, and especially relates to a pharmaceutical composition overcoming postoperative sleep disorder. The provided pharmaceutical composition contains a pharmaceutical solvent carrier and dexmedetomidine or pharmaceutically-acceptable salts thereof dissolved in the solvent carrier. The pharmaceutical composition is used to improve postoperative patient sleep structure, thereby improving patient sleep quality. The pharmaceutical composition also is capable of mitigating patient pain, is safe to use and low in cost, and is usable by being matched with one or more of other sedatives, narcotics, hypnotics and opioids.

The invention provides a β2 receptor agonist inhalation aerosol and products containing the inhalation aerosol. The β2 receptor agonist inhalation aerosol of the present invention is composed of active ingredient formoterol or its pharmaceutically acceptable salt, pharmaceutical carrier, pharmaceutical solvent, polyethylene glycol, povidone and hydrofluoroalkane propellant Composition, by adding the appropriate auxiliary material povidone into the product prescription, and strictly limiting the content of each component in the prescription, and using a combination of fluorocarbon-coated metal cans and quantitative metal valves as the container system; the product stability and effectiveness are improved. Pulmonary deposition has obvious advantages and good market prospects.

The invention discloses a sodium alginate-based pH-responsive drug microcapsule, which comprises the following components in parts by weight: 8-12 parts of a hydrophobic vinyl monomer, 0.6-1 part of a cross-linking agent containing a double bond, and a hydrophobic drug 1-2 parts, 3-5 parts of sodium alginate monomer, 0.06-0.1 parts of hydrophilic surfactant, 0.3-0.5 parts of initiator, 20-30 parts of oil-soluble drug solvent and 338-563 parts of water. The preparation method includes: a) weighing each component; b) dissolving hydrophobic vinyl monomer, double bond-containing cross-linking agent and drug in an oil-soluble drug solvent to obtain an oil phase; c) dissolving sodium alginate 1. The surfactant is dissolved in water to obtain a water phase; d) Add the oil phase to the water phase and emulsify to obtain an oil / water emulsion; e) After the oil / water emulsion is heated up, add an aqueous solution of the initiator dropwise, and after the reaction, centrifuge , washing and drying to obtain microcapsules. The preparation method provided by the invention is simple, easy to operate and has good reproducibility, and the prepared microcapsules have small particle size, uniform distribution, high encapsulation rate, good wall material mechanical properties and stable drug release performance.

The invention discloses a patch for treating rheumatic arthritis and a preparation method thereof. The patch consists of a main medicament for treating rheumatic arthritis, a medicament solvent, a substrate and a penetrating agent, wherein the main medicament consists of triptolide and lidocaine serving as a pain-relieving medicament for relieving rheumatic arthritis pain. The patch is medical controlled-release slow release preparation, has a comprehensive pharmacological action, is used for blocking major development pathologic loops of the rheumatic arthritis disease, and has high specificity and a lasting pharmacological effect; and the preparation method is simple.

The invention relates to the technical field of pharmacy, in particular to a terlipressin acetate preparation and a preparation method thereof. The preparation method of the terlipressin acetate preparation comprises the following steps: freezing and drying a drug solution obtained by mixing terlipressin acetate, glycine and a drug solvent to obtain a terlipressin acetate preparation; The weight ratio of terlipressin acetate and glycine is 1:10-20; the pH of the drug solution is 3.5-4.5. The terlipressin acetate preparation obtained by the specific preparation method of the present invention has a complete appearance, which improves the product yield; the water content of the preparation is low, which improves the stability of the preparation during transportation and storage; it can be quickly reconstituted; and Under the conditions of high temperature and light, the impurity content is small, which improves the safety of the preparation in clinical administration.

A non-addictive analgesic sustained-release drug delivery system, comprising: (1) a narcotic analgesic drug having a concentration of 1 mg / ml-160 mg / ml, the drug being selected from a group consisting of: a local analgesic drug, and the combination of the local analgesic drug and a nonsteroidal analgesic drug and / or an opioid analgesic drug; (2) a drug menstruum in a proportion of 1%-75% (v / v), the menstruum being selected from a group consisting of benzyl alcohol, ethanol, benzyl benzoate, ethyl lactate, and tetrahydrofurfuryl polyethylene glycol ether; and (3) a drug sustained-release formulation having a proportion of 25%-99% (v / v), the sustained-release formulation being selected from a group consisting of natural vegetable oil, synthetic lipid, artificially improved half-natural lipid and derivative thereof. Also disclosed are a preparation process and use of the sustained-release drug delivery system.